查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571424

兒科癌症生物標記市場規模、佔有率、趨勢分析報告：按適應症、按生物標記、按最終用途、細分市場預測，2024-2030 年

Pediatric Cancer Biomarkers Market Size, Share & Trends Analysis Report By Indication (Leukemia, Neuroblastoma, CNS Tumors, Lymphoma), By Biomarker (Alpha-fetoprotein, Neuron-specific enolase), By End Use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

小兒癌症生物標記市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球兒科癌症生物標記市場規模將達到14.5億美元，2024年至2030年複合年成長率為8.5%。

全球兒童癌症患者數量的增加是市場擴張的主要驅動力。根據 NIH 2023 年 2 月的報告，全球整體每年約有 40 萬名 0-19 歲的兒童和青少年被診斷出罹患癌症。兒童癌症與成人癌症不同，白血病是最常見的癌症，其次是中樞神經系統 (CNS) 腫瘤和淋巴瘤。據各醫療機構稱，兒童癌症比成人癌症更為​​罕見，但隨著診斷技術的進步和認知的提高，被診斷出的機會正在增加。

目前正在進行大量研究工作，以發現新的生物標記，以促進兒童癌症的早期檢測和治療。例如，2024 年 6 月，費城兒童醫院 (CHOP) 的研究人員宣布發現了一種新的基於免疫的生物標記。這種有前途的生物標記可能會徹底改變早期檢測方法，有可能在卵巢癌通常變得明顯之前兩到四年檢測出來。這些突破對於改善兒科腫瘤學的結果和存活率至關重要。隨著研究不斷產生創新的生物標記，市場正在擴大，對開發先進診斷工具的投資和關注也增加。這項進步不僅支持更早、更準確的診斷，而且還推動了整個兒科癌症生物標記市場的成長。

此外，學術機構、研究機構和製藥公司之間的合作正在推動兒科癌症生物標記市場的創新。合作和夥伴關係透過共用專業知識和資源促進新生物標記的開發和檢驗。例如，2022 年 2 月，Lantern Pharma 宣布透過與德克薩斯大學健康科學中心的 Greehey 兒童癌症研究所合作，進一步擴展到兒科癌症領域。研究和官民合作關係將加速先進生物標記的發現和商業化。這些夥伴關係關係透過提高研發過程的效率以及更快、更有效地將新生物標記推向市場來促進市場成長。

此外，醫療保健基礎設施的擴張和改善，特別是在新興市場，正在推動兒科癌症生物標記市場的成長。隨著各個地區的醫療保健系統的發展和現代化，先進診斷技術和生物標記測試的機會正在增加。改善的醫療設施和服務將使兒童癌症生物標記被廣泛採用，從而提高診斷準確性和治療效果。

兒科癌症生物標記市場報告亮點

  • 根據統計，白血病領域佔最大，2023年將達40.8%。
  • 從生物標記來看，CD19、CD20和CD22片段在2023年佔據最大佔有率，為29.7%，因為它們在血癌的診斷和標靶化中發揮重要作用。 CAR-T 細胞療法等標靶治療的進步利用這些生物標記來提高治療效果和患者預後。精準醫學應用的不斷擴大對市場擴張做出了重大貢獻。
  • 以最終用途計算，在投資增加和政府支持的推動下，到 2023 年，醫院部門將佔據最大佔有率，達到 40.5%。醫院正在實施先進的生物標記技術，以提高兒童癌症的診斷準確性和個人化治療。為研發提供資金以及引入創新診斷的激勵措施等政府措施正在支持市場擴張。
  • 由於先進的研究、不斷增加的癌症發病率以及對醫療基礎設施的大量投資，北美兒科癌症生物標記市場在全球整體市場中佔據主導地位，到 2023 年將佔 43.8% 的銷售佔有率。診斷技術的增強和對個人化醫療的關注正在推動市場擴張，以及對兒童癌症研究和治療的大量資金和政府支持。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章兒科癌症生物標記市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 小兒癌症生物標記市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章兒科癌症生物標記市場：適應症估計和趨勢分析

  • 細分儀表板
  • 小兒癌症生物標記市場：適應症變異分析
  • 小兒癌症生物標記市場：按適應症分類的前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 白血病
  • 神經母細胞瘤
  • 中樞神經系統腫瘤
  • 淋巴瘤
  • 其他

第5章兒科癌症生物標記市場：生物標記估計和趨勢分析

  • 細分儀表板
  • 小兒癌症生物標記市場：生物標記波動分析
  • 小兒癌症生物標記市場：生物標記展望
  • 2018-2030年市場規模、預測及趨勢分析
  • 胎兒球蛋白(AFP)
  • 神經元特異性烯醇化酶 (NSE)
  • CD19、CD20、CD22
  • ALK（間變性淋巴瘤受體蛋白酪氨酸激酶基因）
  • 其他

第6章兒科癌症生物標記市場：最終用途估計和趨勢分析

  • 細分儀表板
  • 兒科癌症生物標記市場：最終用途變異分析
  • 小兒癌症生物標記市場：依最終用途分類的前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 醫院
  • 診斷實驗室
  • 腫瘤中心
  • 調查機構

第7章小兒癌症生物標記市場：區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 市場參與企業分類
  • 主要市場參與企業的最新趨勢和影響分析
  • 策略規劃
  • 主要企業簡介
    • F. Hoffmann-La Roche Ltd
    • Abbott
    • Siemens Healthineers
    • Thermo Fisher Scientific
    • QIAGEN
    • Myriad Genetics
    • Beckman Coulter
    • Bio-Rad Laboratories
    • Agilent Technologies
    • BIOMERIEUX
    • RayBiotech, Inc
    • Randox Laboratories Ltd.
Product Code: GVR-4-68040-440-6

Pediatric Cancer Biomarkers Market Growth & Trends:

The global pediatric cancer biomarkers market size is anticipated to reach USD 1.45 billion by 2030 and is projected to grow at a CAGR 8.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rise in the number of pediatric cancer cases globally is a major driver for market expansion. According to a February 2023 NIH report, approximately 400,000 children and adolescents aged 0-19 are diagnosed with cancer globally each year. Pediatric cancers are distinct from those in adults, with the most prevalent types being leukemias, followed by central nervous system (CNS) tumors and lymphomas. According to various health organizations, pediatric cancers, while rarer than adult cancers, are increasingly being diagnosed due to better diagnostic technologies and heightened awareness.

Significant research efforts are uncovering novel biomarkers that can enhance early detection and treatment of pediatric cancers. For instance, in June 2024, researchers at the Children's Hospital of Philadelphia (CHOP) announced the discovery of a new immune-based biomarker. This promising biomarker could revolutionize early detection methods, potentially identifying ovarian cancer two to four years before it typically manifests. Such breakthroughs are crucial for improving pediatric oncology treatment outcomes and survival rates. As research continues to yield innovative biomarkers, the market is expanding, with increased investments and focus on developing advanced diagnostic tools. This progress not only supports earlier and more accurate diagnosis but also drives the overall growth of the pediatric cancer biomarkers market.

Additionally, collaboration between academic institutions, research organizations, and pharmaceutical companies drives innovation in the pediatric cancer biomarkers market. Joint research efforts and partnerships facilitate developing and validating new biomarkers through shared expertise and resources. Collaborative initiatives, such as multi-center For instance, in February 2022, Lantern Pharma announced its expansion into additional pediatric cancers through a partnership with The Greehey Children Cancer Research Institute at the University of Texas Health Science Center. studies and public-private partnerships, accelerate the discovery and commercialization of advanced biomarkers. These partnerships enhance the efficiency of research and development processes, contributing to market growth by bringing novel biomarkers to market more rapidly and effectively.

Furthermore, the expansion and improvement of healthcare infrastructure, particularly in emerging markets, are facilitating the growth of the pediatric cancer biomarkers market. As healthcare systems in various regions develop and modernize, there is greater access to advanced diagnostic technologies and biomarker tests. Improved healthcare facilities and services enable the broader implementation of pediatric cancer biomarkers, enhancing diagnostic accuracy and treatment efficacy.

Pediatric Cancer Biomarkers Market Report Highlights:

  • Based on indication, the leukemia segment held the largest share of 40.8% in 2023, owing to the high incidence and need for early detection of this cancer type.
  • Based on biomarker, the CD19, CD20, and CD22 segments held the largest share of 29.7% in 2023, due to their critical roles in diagnosing and targeting hematological cancers. Advances in targeted therapies, such as CAR-T cell therapies, utilize these biomarkers to improve treatment efficacy and patient outcomes. Their growing application in precision medicine is significantly contributing to market expansion.
  • In terms of end use, the hospital segment held the largest share of 40.5% in 2023, driven by increasing investments and government support. Hospitals are adopting advanced biomarker technologies to improve diagnostic accuracy and personalized treatments for pediatric cancers. Government initiatives, such as funding for research and development and incentives for implementing innovative diagnostics, are bolstering market expansion.
  • North America pediatric cancer biomarkers market dominated the overall global market and accounted for the 43.8% revenue share in 2023due to advanced research, increasing cancer incidence, and significant investments in healthcare infrastructure. Enhanced diagnostic technologies and a focus on personalized medicine are driving market expansion, alongside substantial funding and supportive government policies for pediatric cancer research and treatment.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Biomarker
    • 1.2.3. End use
    • 1.2.4. Regional Scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Indication outlook
    • 2.2.2. Biomarker outlook
    • 2.2.3. End use outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Pediatric Cancer Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Incidence of Pediatric Cancer
      • 3.2.1.2. Growing Awareness and Government Initiatives
      • 3.2.1.3. Advancements in Genomics and Proteomics
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Costs of Research and Development
      • 3.2.2.2. Complex Regulatory Requirements
  • 3.3. Pediatric Cancer Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Pediatric Cancer Biomarkers Market: Indication Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Pediatric Cancer Biomarkers Market: Indication Movement Analysis
  • 4.3. Pediatric Cancer Biomarkers Market by Indication Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Leukemia
    • 4.5.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Neuroblastoma
    • 4.6.1. Neuroblastoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. CNS Tumors
    • 4.7.1. CNS Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Lymphoma
    • 4.8.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pediatric Cancer Biomarkers Market: Biomarker Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Pediatric Cancer Biomarkers Market: Biomarker Movement Analysis
  • 5.3. Pediatric Cancer Biomarkers Market by Biomarker Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Alpha-fetoprotein (AFP)
    • 5.5.1. Alpha-fetoprotein (AFP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Neuron-specific enolase (NSE)
    • 5.6.1. Neuron-specific enolase (NSE) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. CD19, CD20, CD22
    • 5.7.1. CD19, CD20, CD22 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. ALK (anaplastic lymphoma receptor tyrosine kinase gene)
    • 5.8.1. ALK (anaplastic lymphoma receptor tyrosine kinase gene) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Pediatric Cancer Biomarkers Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Pediatric Cancer Biomarkers Market: End Use Movement Analysis
  • 6.3. Pediatric Cancer Biomarkers Market by End Use Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Hospital
    • 6.5.1. Hospital Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Diagnostic Laboratories
    • 6.6.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Oncology Centers
    • 6.7.1. Oncology Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Research Institutions
    • 6.8.1. Research Institutions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pediatric Cancer Biomarkers Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Recent Developments & Impact Analysis by Key Market Participants
  • 8.3. Strategy Mapping
  • 8.4. Key Company Profiles
    • 8.4.1. F. Hoffmann-La Roche Ltd
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Abbott
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Siemens Healthineers
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Thermo Fisher Scientific
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. QIAGEN
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Myriad Genetics
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Beckman Coulter
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Bio-Rad Laboratories
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Agilent Technologies
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. BIOMERIEUX
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. RayBiotech, Inc
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives
    • 8.4.12. Randox Laboratories Ltd.
      • 8.4.12.1. Company overview
      • 8.4.12.2. Financial performance
      • 8.4.12.3. Product benchmarking
      • 8.4.12.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 4 Global pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 5 Global pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America pediatric cancer biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 8 North America pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 9 North America pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 10 U.S. pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 11 U.S. pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 12 U.S. pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 13 Canada pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 14 Canada pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 15 Canada pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Mexico pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 17 Mexico pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 18 Mexico pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe pediatric cancer biomarkers market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Europe pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 22 Europe pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 23 UK pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 24 UK pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 25 UK pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Germany pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 27 Germany pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 28 Germany pediatric cancer biomarkers market, by end use 2018 - 2030 (USD Million)
  • Table 29 France pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 30 France pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 31 France pediatric cancer biomarkers market, by end use 2018 - 2030 (USD Million)
  • Table 32 Italy pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Italy pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 34 Italy pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Spain pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 36 Spain pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 37 Spain pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 38 Denmark pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 39 Denmark pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 40 Denmark pediatric cancer biomarkers market, by end use 2018 - 2030 (USD Million)
  • Table 41 Norway pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 42 Norway pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 43 Norway pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Sweden pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 45 Sweden pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 46 Sweden pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific pediatric cancer biomarkers market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 51 Japan pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 52 Japan pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 53 Japan pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 54 China pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 55 China pediatric cancer biomarkers market, by biomarker 2018 - 2030 (USD Million)
  • Table 56 China pediatric cancer biomarkers market, by end use 2018 - 2030 (USD Million)
  • Table 57 India pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 58 India pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 59 India pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 60 Australia pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 61 Australia pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 62 Australia pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 63 South Korea pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 64 South Korea pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 65 South Korea pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 66 Thailand pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 67 Thailand pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 68 Thailand pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Latin America pediatric cancer biomarkers market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 71 Latin America pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 72 Latin America pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 73 Brazil pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 74 Brazil pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 75 Brazil pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 76 Argentina pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 77 Argentina pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 78 Argentina pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa pediatric cancer biomarkers market, by country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 83 South Africa pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 84 South Africa pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 85 South Africa pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 89 UAE pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 90 UAE pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 91 UAE pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 93 Kuwait pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 94 Kuwait pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Pediatric cancer biomarkers market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Pediatric cancer biomarkers market, indication outlook key takeaways (USD Million)
  • Fig. 12 Pediatric cancer biomarkers market: indication movement analysis 2023 & 2030 (USD Million)
  • Fig. 13 Leukemia market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Neuroblastoma market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 CNS tumors market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Lymphoma market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Pediatric cancer biomarkers market, biomarker outlook key takeaways (USD Million)
  • Fig. 19 Pediatric cancer biomarkers market: biomarker movement analysis 2023 & 2030 (USD Million)
  • Fig. 20 Pediatric market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Alpha-fetoprotein (AFP) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Neuron-specific enolase (NSE) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 CD19, CD20, CD22 market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 ALK (anaplastic lymphoma receptor tyrosine kinase gene) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Pediatric cancer biomarkers market, end use outlook key takeaways (USD Million)
  • Fig. 27 Pediatric cancer biomarkers market: end use movement analysis 2023 & 2030 (USD Million)
  • Fig. 28 Hospital market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Diagnostic laboratories market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Oncology centers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Research institutions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Pediatric cancer biomarkers market: regional key takeaways (USD Million)
  • Fig. 33 Pediatric cancer biomarkers market: regional outlook, 2023 & 2030 (USD Million)
  • Fig. 34 North America pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 US pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Canada pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Europe pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 UK pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Germany pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 France pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Spain pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Italy pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Norway pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 China pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Japan pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 India pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 South Korea pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Australia pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 South Africa pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Saudi Arabia pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 UAE pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 List of key emerging company's/biomarker disruptors/innovators